JP4516694B2 - 新規なポリヒドロキシピラジン誘導体、それらの製造及びそれらを含有する製薬学的組成物 - Google Patents

新規なポリヒドロキシピラジン誘導体、それらの製造及びそれらを含有する製薬学的組成物 Download PDF

Info

Publication number
JP4516694B2
JP4516694B2 JP2000593595A JP2000593595A JP4516694B2 JP 4516694 B2 JP4516694 B2 JP 4516694B2 JP 2000593595 A JP2000593595 A JP 2000593595A JP 2000593595 A JP2000593595 A JP 2000593595A JP 4516694 B2 JP4516694 B2 JP 4516694B2
Authority
JP
Japan
Prior art keywords
choh
cycloalk
alk
group
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000593595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534513A (ja
Inventor
ブーシヤール，エルベ
コメルソン，アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of JP2002534513A publication Critical patent/JP2002534513A/ja
Application granted granted Critical
Publication of JP4516694B2 publication Critical patent/JP4516694B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000593595A 1999-01-11 2000-01-07 新規なポリヒドロキシピラジン誘導体、それらの製造及びそれらを含有する製薬学的組成物 Expired - Fee Related JP4516694B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9900186A FR2788274B1 (fr) 1999-01-11 1999-01-11 Nouveaux derives de polyhydroxypyrazines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR99/00186 1999-01-11
PCT/FR2000/000026 WO2000042027A1 (fr) 1999-01-11 2000-01-07 Nouveaux derives de polyhydroxypyrazines, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
JP2002534513A JP2002534513A (ja) 2002-10-15
JP4516694B2 true JP4516694B2 (ja) 2010-08-04

Family

ID=9540746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000593595A Expired - Fee Related JP4516694B2 (ja) 1999-01-11 2000-01-07 新規なポリヒドロキシピラジン誘導体、それらの製造及びそれらを含有する製薬学的組成物

Country Status (24)

Country Link
US (1) US6818637B2 (ru)
EP (1) EP1140861B1 (ru)
JP (1) JP4516694B2 (ru)
KR (1) KR100648324B1 (ru)
CN (1) CN1145615C (ru)
AT (1) ATE244226T1 (ru)
AU (1) AU774627B2 (ru)
BR (1) BR0007449B1 (ru)
CA (1) CA2359463C (ru)
CZ (1) CZ301380B6 (ru)
DE (1) DE60003631T2 (ru)
DK (1) DK1140861T3 (ru)
EA (1) EA003550B1 (ru)
ES (1) ES2198273T3 (ru)
FR (1) FR2788274B1 (ru)
HU (1) HU228761B1 (ru)
IL (2) IL143945A0 (ru)
NO (1) NO320398B1 (ru)
NZ (1) NZ512911A (ru)
PL (1) PL200682B1 (ru)
PT (1) PT1140861E (ru)
SK (1) SK286389B6 (ru)
WO (1) WO2000042027A1 (ru)
ZA (1) ZA200105657B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100425596C (zh) * 2006-03-29 2008-10-15 中国烟草总公司郑州烟草研究院 脱氧果糖嗪的制备方法
CN101697972B (zh) * 2009-11-16 2011-08-10 朱峰 新曲霉酸在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2238081A1 (en) * 1995-11-22 1997-05-29 S. Jane Desolms Inhibitors of farnesyl-protein transferase
FR2744365B1 (fr) * 1996-02-06 1998-02-27 Inst Malgache Rech Appl Melanges isolables a partir de graines d'eugenia jambolana lamarck, leur preparation et l'utilisation de ces melanges et certains de leurs constituants comme medicaments
FR2766185B1 (fr) * 1997-07-18 2001-06-15 Rhone Poulenc Rorer Sa Medicaments contenant en tant que principe actif au moins un derive substitue de polyhydroxylalkylpyrazines, les nouveaux derives polyhydroxylalkylpyrazines et leur preparation

Also Published As

Publication number Publication date
EA003550B1 (ru) 2003-06-26
FR2788274A1 (fr) 2000-07-13
NO20013416D0 (no) 2001-07-10
SK9762001A3 (en) 2001-12-03
CA2359463C (fr) 2009-09-15
EP1140861A1 (fr) 2001-10-10
CN1352638A (zh) 2002-06-05
DK1140861T3 (da) 2003-10-20
NO20013416L (no) 2001-09-06
FR2788274B1 (fr) 2001-02-09
SK286389B6 (sk) 2008-09-05
IL143945A (en) 2006-04-10
JP2002534513A (ja) 2002-10-15
NZ512911A (en) 2003-10-31
HU228761B1 (en) 2013-05-28
CZ20012483A3 (cs) 2001-10-17
KR100648324B1 (ko) 2006-11-23
PT1140861E (pt) 2003-11-28
DE60003631T2 (de) 2004-06-03
US6818637B2 (en) 2004-11-16
EP1140861B1 (fr) 2003-07-02
HUP0105104A3 (en) 2002-09-30
WO2000042027A1 (fr) 2000-07-20
ES2198273T3 (es) 2004-02-01
EA200100767A1 (ru) 2001-12-24
IL143945A0 (en) 2002-04-21
KR20010101456A (ko) 2001-11-14
PL200682B1 (pl) 2009-01-30
PL348768A1 (en) 2002-06-03
CA2359463A1 (fr) 2000-07-20
BR0007449A (pt) 2001-10-16
DE60003631D1 (de) 2003-08-07
CN1145615C (zh) 2004-04-14
HUP0105104A2 (hu) 2002-07-29
AU774627B2 (en) 2004-07-01
BR0007449B1 (pt) 2011-08-09
ZA200105657B (en) 2002-10-10
NO320398B1 (no) 2005-11-28
AU3051500A (en) 2000-08-01
US20020077324A1 (en) 2002-06-20
CZ301380B6 (cs) 2010-02-03
ATE244226T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
JP4516694B2 (ja) 新規なポリヒドロキシピラジン誘導体、それらの製造及びそれらを含有する製薬学的組成物
JP4443034B2 (ja) ポリヒドロキシアルキルピラジン誘導体、それらの製造およびそれらを含有する医薬品
JP4590099B2 (ja) ポリヒドロキシアルキルピラジン誘導体及びそれらの製造及びそれらを含有する薬剤
MXPA01006975A (en) Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same
FR2766182A1 (fr) Medicaments contenant des derives de polyhydroxyalkylpyrazine, les nouveaux derives de polyhydroxyalkylpyrazine et leur preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061228

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100511

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100517

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130521

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130521

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees